FDG PET/CT as a prognostic biomarker in the era of molecular-targeting therapies: max SUVmax predicts survival of patients with advanced renal cell carcinoma

• Published in: BMC cancer Vol. 16; no. 1; p. 67
• Main Authors: Nakaigawa, Noboru, Kondo, Keiichi, Tateishi, Ukihide, Minamimoto, Ryogo, Kaneta, Tomohiro, Namura, Kazuhiro, Ueno, Daiki, Kobayashi, Kazuki, Kishida, Takeshi, Ikeda, Ichiro, Hasumi, Hisashi, Makiyama, Kazuhide, Kubota, Yoshinobu, Inoue, Tomio, Yao, Masahiro
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 08.02.2016; BioMed Central
• Subjects: Adult; Aged; Aged, 80 and over; Biological activity; Biological markers; Carcinoma, Renal cell; Carcinoma, Renal Cell - diagnostic imaging; Carcinoma, Renal Cell - pathology; Carcinoma, Renal Cell - surgery; Care and treatment; Complications and side effects; Development and progression; Enrollments; Female; Fluorodeoxyglucose F18 - therapeutic use; Glucose - metabolism; Humans; Kidney cancer; Male; Medical imaging; Medical prognosis; Metastasis; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Recurrence, Local - diagnostic imaging; Neoplasm Recurrence, Local - pathology; Neoplasm Recurrence, Local - therapy; Neoplasm Staging; Nephrectomy; Pathology; Patient outcomes; Patients; PET imaging; Positron-Emission Tomography; Prognosis; Tomography; Tomography, X-Ray Computed; Treatment Outcome; United States
• DOI: 10.1186/s12885-016-2097-4
• ISSN: 1471-2407

Various molecular-targeting therapies have become available for the treatment of advanced renal cell carcinoma (RCC). Accurate prognostication is desirable for choosing the appropriate treatment for individual patients. (18)F-2-fluoro-2-deoxyglucose positron-emission tomography/computed tomography (FDG PET/CT) is a non-invasive tool for evaluating glucose accumulation, which can be an index of biological characteristics of cancer. We prospectively evaluated FDG PET/CT as a prognostic indicator in patients with advanced RCC. A total of 101 patients slated for different systematic therapies for advanced RCC were enrolled between 2008 and 2014. A total of 61 patients had recurrent RCC (58 metastatic and 3 regional) and 40 patients had stage IV RCC (36 metastatic and 4 locoregional). Sixteen patients had not undergone nephrectomy. Pre-treatment FDG PET/CT was performed, and the max SUVmax (the highest SUV measurement in each patient) was recorded. The max SUVmax was compared with different clinical risk factors as prognostic indicators. The median observation period was 18 months (range 1-70 months). The max SUVmax of the 101 subjects ranged from undetectable to 23.0 (median 6.9). Patients with high max SUVmax had a poor prognosis. Multivariate analysis with standard risk factors revealed that max SUVmax was an independent predictor of survival (p < 0.001; hazard ratio 1.265; 95% confidence interval 1.159-1.380). A cutoff of 8.8 for max SUVmax advocated in our previous report was highly significant (p < 0.0001). When we subclassified the max SUVmax values, the median overall survival of subjects with max SUVmax < 7.0 was 41.9 months. That of subjects with max SUVmax between 7.0 and 12.0 was 20.6 months. That of subjects with max SUVmax ≥ 12.0 was 4.2 months. The differences were statistically significant. Pretreatment max SUVmax assessed by FDG PET/CT is a useful prognostic marker for patients with advanced RCC, providing helpful information for clinical decision making.